News SCOTUS backs generic firm Hikma in skinny label dispute SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.
News 'Skinny' generic Vascepa label case reaches US Supreme Court SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.
News Amarin’s Vascepa gets priority review for cardiovascular lab... Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.